Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT06824129

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR — Active Not Recruiting • Infectious Disease • NCT06824129.

📅 29 Jul 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT06824129
Start
2025-12-23
Completion
2026-08
ClinicaliQ Trial Snapshot
  • Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR — Active Not Recruiting • Infectious Disease • NCT06824129.
  • A rapid urine test accurately identifies bacteria causing urinary tract infections and detects antibiotic resistance.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment Conditions: Complicated Urinary Tract Infection Lead Sponsor: QIAGEN Gaithersburg, Inc Planned Enrollment: 1500 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Nearly 400 antibiotic-resistant infections each week in 2024
Infectious Disease · UKHSA · 29 Jun 2026
Antibiotic resistance remains a significant burden with ~400 resistant infections weekly in 2024, despite NHS prescribing falling below pre-pandemic levels Private sector…
View brief →
Clinical Brief
Antibiotics and MenB vaccination to be offered to young people in Dorset
Infectious Disease · UKHSA · 17 Apr 2026
Three cases of invasive meningococcal disease in a Dorset area have triggered a targeted public health response offering prophylactic antibiotics and MenB…
View brief →
Clinical Brief
New HIV report shows progress but inequalities persist in access to testing, PrEP and early diagnosis
Infectious Disease · UKHSA · 14 May 2026
Black African heterosexual women show disproportionately low HIV testing uptake in sexual health services, highlighting a persistent gap in screening coverage among…
View brief →
Clinical Brief
What is the UK Covid inquiry and how does it work?
Infectious Disease · BBC Health · 16 Apr 2026
The UK Covid inquiry's fourth report acknowledges the national vaccination programme as an "extraordinary feat" of public health delivery during the pandemic.…
View brief →
Clinical Brief
People Fixing The World
Infectious Disease · BBC Health · 01 Sep 2026
Sepsis Prevention, Detection and Treatment Early recognition is critical – Sepsis remains a major cause of mortality and morbidity; improving awareness and…
View brief →
Clinical Brief
Travellers reminded to take precautions to avoid infections abroad this summer
Infectious Disease · UKHSA · 14 Jul 2026
Dengue and Zika cases imported into the UK continue to rise seasonally; clinicians should maintain heightened suspicion for these infections in patients…
View brief →